Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Conexeu Sciences Inc.CNXU · Entity 6454 | Director · Chief Commercial Officer | September 25, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Conexeu Sciences Inc.
Report date September 25, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,812,500 |
Reported balance
After 2026-09-25 transaction · row 1
1 source rowRow 1 · 2026-09-25 · Exercise / conversion · Acquired 750,000 · Balance 1,812,500 F1: The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. |
| Performance WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2030-06-05 | Direct | 250,000 |
Reported balance
After 2026-09-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-25 · Exercise / conversion · Disposed 750,000 · Balance 250,000 F1: The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. |
| Common StockSEC Table I · non-derivative | IndirectBy 0865546 B.C. Ltd. | 431,250 |
Reported balance
Holding disclosure · report date 2026-09-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 431,250 F2: Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
F2: Held by 0865546 B.C. Ltd., over which the Reporting Person has sole voting and dispositive power.
F3: The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 25, 2026 Filed Sep 28, 2026 21:38 UTC | Conexeu Sciences Inc. CNXU · Entity 6454 | Exercise / conversionPerformance Warrants · Derivative | 750,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-26-005090 · form4.xml · derivative · entry 3 Bogart David Robert · CIK 0002128417 · Director · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 750,000 shares Expires 2030-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · price: The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. F3 · derivative.exercise_date: The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. F3 · derivative.expiration_date: The Performance Warrants were granted on June 5, 2025 and have an exercise price of $0.001 and a term of 5 years. The Performance Warrants were granted for services rendered to the issuer and no price was paid for the Performance Warrants. 750,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration. Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 21:38 UTC | Conexeu Sciences Inc. CNXU · Entity 6454 | Exercise / conversionCommon Stock | 750,000 | $0.00 | $750.00 |
DisclosureSEC source: 0001062993-26-005090 · form4.xml · nonDerivative · entry 1 Bogart David Robert · CIK 0002128417 · Director · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,812,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction is also exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.